



December 22, 2023

PeptiDream Inc.  
<https://www.peptidream.com>  
(Securities Code: 4587 TSE Prime Market)

## **PeptiDream and LinqMed Announce Strategic Partnership for the Development and Commercialization of <sup>64</sup>Cu-ATSM in Japan**

KANAGAWA, JAPAN – December 22<sup>nd</sup>, 2023 – PeptiDream Inc. (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced that PDRadiopharma Inc. (President: Susumu Tanahashi, Headquarters: Chuo-ku, Tokyo, Japan, “PDRadiopharma”), a wholly owned subsidiary of PeptiDream, has entered into a strategic partnership with LinqMed Inc. (President: Yukie Yoshii, Headquarters: Chiba-shi, Chiba, Japan, “LinqMed”) for the clinical development, regulatory filing and commercialization in Japan of <sup>64</sup>Cu-ATSM, a targeted radiotherapeutic for the potential treatment of malignant brain tumors.

The radiotherapeutic, <sup>64</sup>Cu-ATSM, is a small molecule diacetyl-bis(*N*<sub>4</sub>-methylthiosemicarbazone) conjugated to the radioisotope Copper 64 (<sup>64</sup>Cu). Most tumors are known to create a hypoxic microenvironment within and around the tumor, due to increased oxygen consumption by rapidly proliferating tumor cells and an inadequate oxygen supply due to abnormal tumor angiogenesis, and <sup>64</sup>Cu-ATSM localizes to these hypoxic tumor microenvironments, delivering the therapeutic <sup>64</sup>Cu payload, which induces irreversible DNA damage and results in tumor cell death.

In Japan, there are approximately 4,000 – 5,000 new cases of gliomas reported each year, with the 5-year overall survival (OS) rate at 15.5%, a median OS of 18 months, and a recurrence rate of 51%. There are currently no effective or established treatments for patients with these recurrent malignant brain tumors to which standard treatments, surgical excision, stereotactic irradiation, or chemotherapy, proved ineffective.

Phase 1 open-label interventional dose escalation safety study has been conducted at the National Cancer Center (jRCT2091220362), in patients with recurrent malignant brain tumors (glioblastoma, glioma, PCNSL, and/or malignant meningiomas) that had already undergone standard treatments. The primary outcome of the study is to determine the occurrence of dose limiting toxicity (DLT), with a secondary outcome of determining response rate, progression-free survival (PFS), estimated effective dose by internal exposure evaluation, expression of adverse event, steroid non-incremental rate, and Karnofsky Performance Status (KPS) non-deterioration rate. The completed study is expected to read out in the first half of 2024.

Through this partnership, LinqMed will continue to lead development activities of <sup>64</sup>Cu-ATSM and PDRadiopharma will lead regulatory filing and commercialization activities in Japan. Under the strategic partnership agreement, the companies will share costs and profits for the development and commercialization of <sup>64</sup>Cu-ATSM in Japan. Additionally, PeptiDream participated in LinqMed’s recent Series A, and is now a shareholder in LinqMed.

*“We are delighted to partner with LinqMed to add  $^{64}\text{Cu}$ -ATSM to our growing portfolio of targeted radiotherapy products. In the radiopharmaceutical field, Copper-64 is proving to be a true Theranostics radionuclide, with promise as both a therapeutic and diagnostic agent, and LinqMed has been a pioneering leader in this approach. We are excited about the new possibilities the Copper-64 technology brings, as we continue to leverage the unique strengths of radiopharmaceuticals to bring highly efficacious innovative medicines to patients.”* said **Kiyofumi Kaneshiro, Ph.D., Board Director of PDRadiopharma & CFO of PeptiDream**

*“LinqMed has been pioneering the discovery and development of Copper-64 based radiopharmaceuticals in Japan. We have developed extensive Copper-64 technology and expertise, as well as manufacturing capabilities, and we are very excited about the therapeutic potential of  $^{64}\text{Cu}$ -ATSM for the treatment of patients with recurrent brain cancer. Partnering with PDRadiopharma, which has a long history in the radiopharmaceutical field in Japan with expertise in regulatory and commercialization, will allow LinqMed to more rapidly bring this promising treatment to patients in need that currently have limited therapeutic options.”* said **Yukie Yoshii, Ph.D., CEO of LinqMed**.

#### **About PeptiDream Inc.**

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug conjugate (PDC) and multi-functional peptide conjugates (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit [www.peptidream.com](http://www.peptidream.com)

#### **About LinqMed Inc.**

LinqMed Inc. is a clinical stage biopharmaceutical company developing radiopharmaceuticals with the aim of providing "innovative 'visible' anti-cancer treatments" to society as quickly as possible in order to achieve its mission of “Link for Life - connecting cutting-edge science and medicine -”. The company was established based on technologies from the National Institutes for Quantum Science and Technology (QST) and is developing therapeutic and diagnostic agents for cancer using  $^{64}\text{Cu}$ , a radioactive isotope of copper. For more information, please visit their website at <https://www.linqmed.co.jp/>.

#### **Inquiries:**

##### **PeptiDream Inc.**

Contact: Yuko Okimoto, IR & Public Affairs

Email: [info@peptidream.com](mailto:info@peptidream.com)